Strong Prescription Growth and Competitive Advantage Drive Buy Rating for Arcutis Biotherapeutics
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
verywellhealth6d
Body Cream vs. Body Lotion—Find Out Which Your Skin Needs
Both body creams and lotions hydrate skin, but they have a few key differences. The main is consistency. Here’s how to tell ...
Allure on MSN6d
15 Best Barrier Repair Treatments to Coddle Stressed Skin
Whatever TikTok trends or buzzy skin-care ingredients are out there, heed this piece of advice: Don't compromise your barrier ...